Open Access
Qatar Medical Journal, volume 2022, issue 3
Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
Fateen Ata
1
,
Zohaib Yousaf
1
,
Fathima Z. Zahir
1
,
Anas Mohamed Babiker
1
,
Amer Ali Farooqi
1
,
Mousa Ahmad Al Hiyari
1
,
Adel Issam Al Bozom
1
,
Ahmed Hatim. Mohamed
1
,
Abdulqadir J. Nashwan
2
,
Mohamed A. Yassin
3
2
Publication type: Journal Article
Publication date: 2022-09-15
Journal:
Qatar Medical Journal
scimago Q3
SJR: 0.295
CiteScore: 1.8
Impact factor: —
ISSN: 02538253, 22270426
General Medicine
Found
Top-30
Journals
|
1
2
3
|
|
|
Cureus
3 publications, 100%
|
|
|
1
2
3
|
Publishers
|
1
2
3
|
|
|
Springer Nature
3 publications, 100%
|
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Ata F. et al. Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population // Qatar Medical Journal. 2022. Vol. 2022. No. 3.
GOST all authors (up to 50)
Copy
Ata F., Yousaf Z., Zahir F. Z., Mohamed Babiker A., Ali Farooqi A., Ahmad Al Hiyari M., Al Bozom A. I., Mohamed A. H., Nashwan A. J., Yassin M. A. Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population // Qatar Medical Journal. 2022. Vol. 2022. No. 3.
Cite this
RIS
Copy
TY - JOUR
DO - 10.5339/qmj.2022.22
UR - https://doi.org/10.5339/qmj.2022.22
TI - Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
T2 - Qatar Medical Journal
AU - Ata, Fateen
AU - Yousaf, Zohaib
AU - Zahir, Fathima Z.
AU - Mohamed Babiker, Anas
AU - Ali Farooqi, Amer
AU - Ahmad Al Hiyari, Mousa
AU - Al Bozom, Adel Issam
AU - Mohamed, Ahmed Hatim.
AU - Nashwan, Abdulqadir J.
AU - Yassin, Mohamed A.
PY - 2022
DA - 2022/09/15
PB - Hamad Medical Corporation
IS - 3
VL - 2022
SN - 0253-8253
SN - 2227-0426
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2022_Ata,
author = {Fateen Ata and Zohaib Yousaf and Fathima Z. Zahir and Anas Mohamed Babiker and Amer Ali Farooqi and Mousa Ahmad Al Hiyari and Adel Issam Al Bozom and Ahmed Hatim. Mohamed and Abdulqadir J. Nashwan and Mohamed A. Yassin},
title = {Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population},
journal = {Qatar Medical Journal},
year = {2022},
volume = {2022},
publisher = {Hamad Medical Corporation},
month = {sep},
url = {https://doi.org/10.5339/qmj.2022.22},
number = {3},
doi = {10.5339/qmj.2022.22}
}